İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2020

Real world data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment for chronic Hepatitis C really effective?

The Turkish Journal of Gastroenterology

YÖKSİS OpenAlex Açık erişim · green SJR Q3 JCR Q4 TR Index Atıf 3 Yüzdelik 50.1% FWCI 0.23
Yıl
2020
ISSN
2148-5607
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

BACKGROUND: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. METHODS: Data from patients with chronic hepatitis C treated with SOF/LDV ± RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed. RESULTS: A total of 552 patients were included in the study. The mean age of the patients was 51.28 ± 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV ± RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect. CONCLUSION: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV ± RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.

Konular

  • Hepatitis C virus research
  • Hepatitis Viruses Studies and Epidemiology
  • Silymarin and Mushroom Poisoning

Birincil konu Hepatitis C virus research

Yazarlar

  1. NEŞE DEMİRTÜRK AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ
  2. BİLGEHAN AYGEN ERCİYES ÜNİVERSİTESİ
  3. REŞİT MISTIK
  4. SILA AKHAN
  5. HÜSEYİN ŞENER BARUT
  6. ONUR URAL SELÇUK ÜNİVERSİTESİ
  7. AYŞE BATIREL
  8. FUNDA ŞİMŞEK
  9. GÜLDEN ERSÖZ
  10. NAZLIM AKTUĞ DEMİR SELÇUK ÜNİVERSİTESİ
  11. NECLA TÜLEK ATILIM ÜNİVERSİTESİ